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Abstract: Autologous stem cell transplantation (ASCT) is a well-established approach to treatment of patients with
relapsed/refractory (R/R) Hodgkin lymphoma (HL) recommended by both the European Society for Medical Oncology
and the National Comprehensive Cancer Network based on the results from randomized controlled studies. However,
a considerable number of patients who receive ASCT will progress/relapse and display suboptimal post-transplant
outcomes. Over recent years, a number of different strategies have been assessed to improve post-ASCT outcomes and
augment HL cure rates. These include use of pre- and post-ASCT salvage therapies and post-ASCT consolidative
therapy, with the greatest benefits demonstrated by targeted therapies, such as brentuximab vedotin. However,
adoption of these new approaches has been inconsistent across different centers and regions.
In this article, we provide a European perspective on the available treatment options and likely future developments in
the salvage and consolidation settings, with the aim to improve management of patients with HL who have a high risk
of post-ASCT failure.
Conclusions: We conclude that early intervention with post-ASCT consolidation improves outcomes in patients with
R/R HL who require ASCT. Future approvals of targeted agents are expected to further improve outcomes and provide
additional treatment options in the coming age of personalized medicine.
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Background
Hodgkin lymphoma (HL) is considered to be a curable
hematological malignancy. The currently available chemo-
therapies and targeted therapies deliver frontline cure rates of
approximately 90% for patients with early- or intermediate-
stage disease and 70–90% for patients with advanced-stage
disease [1–7]. For patients who either relapse or are refractory
to frontline treatment, the standard of care comprises salvage
chemotherapy followed by autologous stem cell transplant-
ation (ASCT) [8–11]. Despite this intensified approach, up to
50% of patients will experience progressive disease following
ASCT [9, 12, 13], representing a population with high-risk
disease. This led to initiation of clinical studies in the 1990s
to improve post-ASCT outcomes and consequently improve
HL cure rates [14, 15], many of which showed less than satis-
factory results, until the introduction of post-ASCT consoli-
dation with brentuximab vedotin, an anti-cluster of
differentiation 30 (CD30) antibody-drug conjugate (ADC).
Brentuximab vedotin is able to improve progression-free sur-
vival (PFS) in patients with relapsed/refractory (R/R) classical
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HL (cHL) and a high risk of relapse post-ASCT [16, 17], and
following its regulatory approval in the R/R cHL consolida-
tion setting, a new generation of targeted therapies are being
developed for use in this high-risk population.
This article will provide a European perspective on the
optimal treatment of patients with high-risk R/R HL in
the peri-ASCT setting, based on the current data from
clinical studies and real-world evidence, with a focus on
use of targeted agents to improve post-ASCT outcomes.
Historical perspective on the role of ASCT in R/R HL
Two randomized studies provide the basis for the use of
high-dose chemotherapy (HDC) plus ASCT as a standard of
care in patients with R/R HL. The British National Lymph-
oma Investigation compared the activity of a combination of
carmustine, etoposide, cytarabine, and melphalan (BEAM)
plus autologous bone marrow transplant (ABMT) versus up
to 3 cycles of mini-BEAM (lower doses of the BEAM drug
combination) without ABMT in patients with R/R HL [18].
Although the study failed to show a significant difference in
overall survival (OS) between arms, there were significant
differences in favor of BEAM + ABMT in event-free survival
(EFS; p = 0.025) and PFS (p = 0.005).
The BEAM-ASCT regimen was also assessed by the Ger-
man Hodgkin Study Group (GHSG) and the Lymphoma
Working Party of the European Group for Blood and Mar-
row Transplantation (EBMT) versus dexamethasone plus
BEAM (Dexa-BEAM) [9]. After 3 years’ follow-up, there
was no significant difference in OS between treatment
groups; however, freedom from treatment failure (FFTF)
was significantly improved in the BEAM-ASCT group com-
pared with the Dexa-BEAM group (55% vs 34%; p = 0.019).
Despite the non-significant survival benefit with BEAM +
ABMT/ASCT, this strategy was established as the historical
standard of care based on the clear benefits on tumor con-
trol over conventional-dose salvage therapy alone. The lack
of a demonstrable OS benefit of HDC+ASCT when com-
pared with conventional chemotherapy in these clinical
studies may be attributed to the small number of patients
in the studies. A later detailed meta-analysis of data from
the two studies suggested a trend towards an OS advantage
for patients receiving HDC+ASCT compared with con-
ventional chemotherapy alone (hazard ratio [HR] 0.67, p =
0.10) [19]. In addition, the use of ASCT later in the course
of the disease may have confounded detection of any po-
tential effects of HDC+ASCT on OS.
Improving post-ASCT outcomes in HL: pre-transplant
strategies
Current conventional salvage chemotherapy
The most widely investigated strategy to improve post-
ASCT outcomes is the optimization of pre-ASCT salvage
chemotherapy. A variety of regimens have been studied, in-
cluding platinum-based dexamethasone, cytarabine, and
cisplatin/doxorubicin, methylprednisolone, high-dose
cytarabine, and cisplatin/etoposide, methylprednisolone,
high-dose cytarabine, and cisplatin (DHAP/ASHAP/
ESHAP [20–24]), ifosfamide-based (MINE/ICE/IVE/IVOx
[25–29]), and gemcitabine-based combinations (GVD/
IGEV/GDP/GemOx/BeGEV) [30–34]. Most of these stud-
ies evaluated the efficacy of salvage chemotherapy in terms
of objective responses and the impact on OS and post-
transplant PFS; reports of the impact on stem cell
mobilization, stem cell quality, and stem cell transplant-
ation (SCT) rates are inconsistent (Table 1). Objective
response rates (ORRs) ranged from 61% with GVD (in
ASCT-naïve patients) to 88/89% with ICE and DHAP [20,
26, 27], and complete response (CR) rate was as low as
17% with GDP and as high as 73% with BeGEV [32, 34].
PFS was 78% with ESHAP in patients who achieved CR,
but 16% in those who achieved partial remission (PR) [24];
ICE treatment resulted in a PFS of 70% [35], but only 53
and 62% with IGEV and BeGEV, respectively [31, 34]. EFS
was 36% with ASHAP and 68% with ICE [22, 26]. OS with
ESHAP was estimated at 35% at 3 years in one study and
73% at 5 years in another study [23, 24]. However, the
absence of prospective randomized studies comparing the
regimens makes it impossible to reach conclusions regard-
ing the superiority of particular combinations. This is
reflected in the current European Society for Medical
Oncology (ESMO) and National Comprehensive Cancer
Network (NCCN) treatment guidelines, which do not rec-
ommend any specific salvage therapy regimen for patients
with R/R HL [10, 11, 36]. Instead, appropriate therapy is
generally selected based on patient-related factors, familiar-
ity of the treatment center with particular regimens, treat-
ment as in-patients versus out-patients, and the toxicity
profile of each salvage regimen – patients with concomi-
tant coronary, pulmonary, or renal diseases may require
different salvage management.
Patients who achieve a response, particularly a CR,
with conventional salvage chemotherapy prior to
ASCT, are likely to have an improved clinical out-
come compared with patients who have partially or
totally chemo-resistant disease at relapse. Moskowitz
et al. reported an analysis of long-term outcomes in
75 patients demonstrating significant improvements
(p < 0.001) in EFS (60% vs 19%), PFS (62% vs 23%),
and OS (66% vs 17%) in patients who responded to
standard-dose second-line therapy after relapse, com-
pared with those who had a poor response, respect-
ively [37]. Similarly, in a prospective analysis of 195
patients treated over a 20-year period, patients who
had achieved a CR with conventional salvage chemo-
therapy and who were still in CR at the time of
ASCT had a 5-year OS of 79%, which dropped to
59% for those in PR, and 17% for those with resistant
disease (p < 0.0001). Corresponding 5-year PFS rates
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were 69% versus 44% versus 14% (p < 0.0001) [38].
More recently, in a phase II study of 97 patients,
those who proceeded to SCT with a positron-
emission tomography (PET)-negative status achieved
an EFS of > 80%, compared with 29% in PET-positive
patients [35]. Collectively, these studies demonstrate
that the aim of any modern salvage therapy is to
produce a deep remission and PET-negative status
prior to undergoing HDC-ASCT. However, ASCT
should not be solely withheld due to lack of PET-
negativity [39].
Can salvage therapy be further improved with conventional
cytotoxic agents?
The GHSG have investigated the concept of escalated
pre-ASCT chemotherapy, delivered as sequential-HDC,
compared with standard HDC, in an effort to improve
treatment outcomes for patients with R/R HL receiving
HDC + ASCT [40]. In the GHSG study of standard ver-
sus intensified BEAM-ASCT following DHAP in patients
with relapsed HL (n = 241), there were no significant dif-
ferences in FFTF (p = 0.56) or OS (0.82) between the
study arms. Toxicity was considerably higher in the
Table 1 Conventional chemotherapy-based salvage regimens assessed in patients with R/R HL
Regimen(s) Patients, N Pre-ASCT response rate Survival data in overall patient group (± ASCT)
MINE [25] 100 ORR = 75% 2-year survival rate 59%
ASHAP [22] 56 ORR = 70% (CR = 34%,
PR = 36%)
OS, 5-year follow-up 41%
EFS, 5-year follow-up 36%
DHAP [20] 102 ORR = 88%,
(CR = 21%, PR = 67%)
NR NR
ESHAP [23] 22 ORR = 73% 50-month follow-up 32% alive and disease-free
3-year estimates OS = 35%
Disease-free = 27%
ESHAP [24] 82 ORR = 67%
(CR = 50%)
OS, 5-year follow-up 72.6%
PFS, 5-year follow-up • Pts achieving CR = 78%
• Pts achieving PR = 16%
p < 0.01)
ICE [26] 65 ORR = 88%
(CR = 26%, PR = 58%)
OS, 43-month follow-up 83%
EFS, 43-month follow-up 68%
ICE [27] R/R HL (n = 13)
non-HL (n = 62)
ORR = 89%
(CR = 29%, PR = 60%)
OS, 24-month follow-up 65% (all pts)
EFS, 24-month follow-up 42% (all pts)
ICE/aICE [35] 97 NR OS, 51-month follow-up 80%
PFS, 51-month follow-up 70%
IVE [28] 51 ORR = 84%
(CR = 60%, good PR = 8%,
PR = 16%)
NR NR
IVOx [29] 34 ORR = 76% (CR = 32%) OS, 5-year follow-up 74%
EFS, 5-year follow-up 63%
GVD pre- or post-ASCT [30] 94 ASCT-naïve pts. ORR = 61%
Prior-SCT pts. ORR = 75%
OS, 3.6-year follow-up • SCT-naïve pts. median ORR = 61%
• Prior-SCT pts. ORR = 75%
EFS, 3.6-year follow-up • SCT-naïve pts. median EFS not reached,
52% progression-free at 4 years
• Prior-SCT pts. median EFS duration 8.5 months
IGEV [31] 91 CR = 53.8%, PR = 27.5% OS, 3-year follow-up 70.03%
PFS, 3-year follow-up 52.98%
BeGEV [34] 59 ORR = 83%
(CR = 73%, PR = 10%)
OS, 2-year follow-up 77.6%
PFS, 2-year follow-up 62.2%
GDP [32] 23 ORR = 69.5%
(CR = 17.3%, PR = 52.2%)
NR NR
GemOx [33] 24 ORR = 71%
(CR = 38%, PR = 33%)
OS, 3-year follow-up Median of 26 months
PFS, 3-year follow-up Median of 14 months
NR not reported, Pts patients
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intensified arm, with increased rates of grade 3/4 adverse
events (AEs), although this did not translate into in-
creased mortality.
Patients who achieve a CR following induction chemo-
therapy are highly likely to respond to post-relapse inter-
ventions [31]. Previous studies in patients with HL who
have experienced multiple relapses have demonstrated
that bendamustine monotherapy has promising activity,
with patients who were ineligible for ASCT, or for
whom ASCT had failed, achieving CR rates of 25–35%
[41–43]. In an open-label phase II study, ORR was 83%
(CR = 73%) following 4 cycles of BeGEV as induction
therapy before ASCT in 43/49 patients. Two-year PFS
and OS rates in the overall patient population were 62.2
and 77.6%, respectively, and 80.8 and 89.3% among pa-
tients who underwent ASCT [34].
Optimization of salvage therapy with the use of
brentuximab vedotin
Brentuximab vedotin is currently approved as a mono-
therapy for adult patients with R/R CD30-positive cHL
following ASCT or following ≥ 2 prior therapies when
ASCT or multi-agent chemotherapy is not a treatment
option [44]. The pivotal phase II SG035–0003 study of
brentuximab vedotin (1.8 mg/kg every 3 weeks [Q3W])
after failed ASCT in 102 patients with R/R HL, reported
median OS of 22.4 months and median PFS of 5.6
months at the primary analysis [45]. With prolonged
follow-up (median 35.1 months) estimated 5-year OS
and PFS rates were 41 and 22%, respectively [46]. Corre-
sponding OS and PFS rates amongst the 33% of patients
who achieved a CR were 64 and 52%, and the median re-
sponse duration was not reached. The prospective phase
IV C25007 study evaluated brentuximab vedotin (1.8
mg/kg Q3W) in 60 R/R HL patients who were unsuit-
able for ASCT or multi-agent chemotherapy [47]. The
ORR was 50% (CR = 12%), 47% of patients were bridged
to ASCT, and the estimated 12-month OS was 86%, thus
enabling patients with high-risk disease to receive ASCT,
even if they had a suboptimal response to frontline treat-
ment or chemotherapy/radiotherapy-based salvage.
Lately, brentuximab vedotin has been assessed alone
and in combination with conventional chemotherapy-
based regimens for salvage therapy prior to ASCT in
several studies (Table 2). A phase II study assessed 4 cy-
cles of standard-dose, single-agent brentuximab vedotin
(1.8 mg/kg Q3W) as salvage treatment following induc-
tion therapy with doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD) and/or bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarba-
zine, and prednisone (BEACOPP) [52]. In 37 patients,
ORR was 69% and CR rate was 35%; 89% of patients
were able to proceed to ASCT, either with or without
additional chemotherapy.
Encouraging results with PET-adapted salvage therapy
have been reported by Moskowitz et al. [16] in a phase
II open-label study to assess the efficacy of 2 cycles of
brentuximab vedotin-based salvage (1.2 mg/kg on days
1, 8, and 15) in patients with R/R HL who had failed one
previous doxorubicin-containing regimen. Following the
first 2 cycles of brentuximab vedotin, 27% of patients
were PET-negative and proceeded directly to ASCT and
69% initiated augmented ifosfamide, carboplatin, and
etoposide (aICE) [16]. Seventy-six percent of patients
achieved PET-negativity prior to HDC/ASCT, thus
maximizing the potential for improved post-ASCT out-
comes. Patients treated with 3 cycles of brentuximab
vedotin also achieved similar rates of PET-negativity
(30%) and proceeded directly to ASCT, whilst the re-
mainder received either aICE or ICE [39]. Prior to trans-
plant, 80% of patients had achieved PET-negativity with
either brentuximab vedotin alone or combined with
aICE/ICE, and with 2 years’ follow-up EFS was 82%.
Brentuximab vedotin combined with standard ICE has
also shown promise in phase I/II clinical studies [50, 51].
In the NCT02227199 study, 20/23 evaluable patients pre-
viously treated with ABVD achieved a PET CR per investi-
gator review following brentuximab vedotin + ICE; 70%
were in PET CR per independent central review [50]. Final
data from the Lymphoma Academic Research Organisa-
tion phase I/II study showed that 69% (n = 27/39) of pa-
tients who received brentuximab vedotin (1.8mg/kg) plus
ICE achieved a complete metabolic response (CMR) and
26% achieved a partial metabolic response. Twenty pa-
tients in CMR went on to receive ASCT [51]. Neither
study reported any unexpected toxicities.
Two brentuximab vedotin + platinum-based chemo-
therapy combinations appear particularly promising:
brentuximab vedotin + DHAP (B + DHAP), and bren-
tuximab vedotin + ESHAP (BrESHAP). In the phase II
BRaVE study, the high metabolic CR rate of 79%
achieved with B + DHAP suggests that this approach is
worth investigating further [48]. Moreover, the Grupo
Español de Linfomas y Trasplantes de Médula Ósea
(GELTAMO) study further demonstrated the potential
for brentuximab vedotin combinations with chemother-
apy in the pre-ASCT setting. After approximately 27
months of follow-up, 74% of patients were FFTF, PFS
was 71%, and OS was 91% [49].
The combination of brentuximab vedotin (1.8mg/kg
Q3W) and bendamustine (90mg/m2 days 1–2 Q3W) was
highly active as first salvage therapy for patients with R/R HL
in a phase I/II study involving 55 patients [53]. ORR was
93% and CR was 74% after a median of 2 cycles of therapy.
Interim results of another phase I/II study have also
demonstrated the utility of 4 cycles of a brentuximab
vedotin (1.8 mg/kg Q3W) combined with nivolumab
(3.0 mg/kg Q3W) combination as initial salvage therapy
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for patients with R/R HL [54]. ORR in all treated pa-
tients (n = 61) was 82%, and CR was 61%.
In summary, single-agent brentuximab vedotin as a
salvage therapy shows activity that is not that different
to that seen with classical chemotherapy regimens, albeit
with a lower systemic toxicity, although these have not
been compared in a prospective, randomized phase III
study. Clinical studies of brentuximab vedotin combined
with chemotherapy build on the demonstrated efficacy
of brentuximab vedotin monotherapy, with high CR
rates observed with combination therapy, and with no
new safety signals. Again, these observations need to be
confirmed in prospective, randomized phase III studies,
such as the BRESELIBET study (NCT04378647) that
was opened to enrolment in June 2020. Despite the low
patient numbers in these studies, brentuximab vedotin
plus chemotherapy regimens are frequently used as sal-
vage therapy in the clinic.
Tandem SCT as a strategy to improve ASCT outcomes
The successful implementation of aggressive tandem
transplant programs in myeloma led the Lymphoma
Study Association (LYSA) and the Société Francaise de
Greffe de Moelle (SFGM) to conduct an exploratory
joint phase II study to assess the feasibility of tandem
ASCT in patients with high-risk HL, defined as primary
refractory disease or ≥ 2 of the following risk factors at
first relapse: time to relapse < 12 months, stage III/IV at
relapse, and relapse within previously irradiated sites
[55]. In the high-risk group, 5-year freedom from second
failure rate was 46%, which was higher than the 30% re-
ported by historical studies, and OS rate was 57%. After
a median follow-up of 10.3 years, respective failure-free
survival and OS rates were 64 and 70% for intermediate-
risk patients and 41 and 47% for high-risk patients [56].
In 2018, the Southwest Oncology Group published re-
sults from a phase II study to assess the efficacy of tan-
dem ASCT for 98 patients with primary progressive or
recurrent HL [57]. After a median of 6.2 years’ follow-
up, 2-year and 5-year PFS rates were 63 and 55%, and 2-
year and 5-year OS rates were 91 and 84%, respectively.
Tandem SCT utilizing ASCT followed by an allogeneic
SCT (allo-SCT) was assessed by the LYSA in a multicenter
observational study of 120 patients with high-risk R/R HL
who were prospectively registered on a French national
database [58]. After 43months’ median follow-up the 2-
year PFS and OS rates were 71 and 85%, respectively, in
tandem-transplanted patients, but with no significant differ-
ence between ASCT–allo-SCT or tandem ASCT options.
A retrospective analysis of patients with R/R HL who
received tandem SCT between January 2004 and Decem-
ber 2015, performed by the Lymphoma Working Party
of the EBMT, found that dual SCT might be effective in
high-risk populations [59]. Three years after dual SCT,
Table 2 Brentuximab vedotin-based salvage regimens assessed in patients with R/R HL
Regimen(s) Patients Response before transplant OS PFS
B + DHAP [48] R/R HL (N = 61) • Metabolic CR 79%
• Metabolic PR 8%
• Progressive disease 7%















vedotin + aICE [16]
R/R HL who had failed one previous
doxorubicin regimen (N = 46)
• ~ 30% of pts. achieved PET-negativity with
brentuximab vedotin alone
• aICE increased PET-negativity rates to ~ 80%
NR 2-year EFS = 82%
PET-adapted brentuximab
vedotin + aICE [50, 51]
First relapse or primary refractory
CD30+ cHL
(N = 24 [50])
(N = 42 [51])
• 87% CR per investigator, 70% per
independent review [50]
• 69.2% CMR [51]
NR 1-year PFS estimate
69% (95% CI 53–81%)
Brentuximab vedotin [52] R/R HL (N = 37) • Best ORR = 69% (CR = 33%)
• 12 pts. with CR received SCT





R/R HL (N = 55) • ORR 92.5%
• CR 73.6%
• 41 patients were mobilized and 40
underwent ASCT
NR 2-year PFS 62.6%
Brentuximab vedotin
+ nivolumab [54]
R/R HL (N = 61) • ORR 82%
• CR 61%
• 54 pts. underwent ASCT
NR 6-month estimated
PFS 89%
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PFS was 53%, OS was 72, 34% of patients had relapsed,
and 13% had non-relapse mortality.
These clinical studies suggest that there may be a place
for tandem SCT in the treatment of R/R HL, although
the exact patient subgroup that will derive the most
benefit from this strategy remains to be defined. These
strategies may become less relevant in the era of novel
agents. Integration of pre-ASCT PET-response assess-
ment, post-ASCT salvage and consolidation therapies,
including targeted agents, may offer higher survival rates
with less intensive regimens.
Improving post-ASCT outcomes in HL: post-transplant
strategies
Despite efforts to optimize pre-ASCT strategies, many pa-
tients will still relapse after receiving ASCT [60]. Use of
post-ASCT consolidation, even when there is no detect-
able residual lymphoma, can prevent or delay relapse or
progression. Prospective and retrospective studies have
demonstrated improved PFS in patients who received
post-ASCT rituximab maintenance compared with no
maintenance in patients with follicular lymphoma [61, 62].
These studies suggest that maintenance therapy plays a
role in suppressing emergence of minimal residual disease
(MRD) leading to relapse. A randomized study by Le
Gouill et al., demonstrated clearance of MRD and im-
proved PFS and OS in patients with mantle cell lymphoma
(MCL) treated with post-ASCT rituximab consolidation
for 3 years [63]. The current HL treatment guidelines fail
to emphasize the importance of the timing of such med-
ical intervention. As relapse/progression tends to occur
soon after ASCT, the greatest therapeutic effect is likely to
be achieved with a consolidation treatment delivered as
early as possible after receipt of ASCT [64].
To ensure that patients are exposed to an effective
consolidation regimen for as long as possible, it is im-
portant that consolidative therapies deliver a combin-
ation of efficacy and acceptable tolerability for patients.
Novel targeted therapies that are either approved or are
under investigation in this setting are discussed below
and summarized in Table 3.
Brentuximab vedotin as consolidation therapy
Consolidation therapy is administered to patients who
may have undetectable residual lymphoma and those
who may already be cured. Therefore, the optimal con-
solidation therapy should have a favorable/low toxicity
profile that does not impair hematopoietic and immuno-
logical recovery post-ASCT, with minimal impact on
non-lymphoid/hematopoietic tissues. As biologic treat-
ment options, such as brentuximab vedotin, are less
toxic than traditional cytotoxic chemotherapy, they may
be an ideal treatment option in this setting.
The utility of brentuximab vedotin as early consolidation
therapy after ASCT in patients with high-risk HL was ex-
plored in the phase III AETHERA study (see Table 3) [65].
Patients enrolled in AETHERA (n = 329) had one of the
following pre-ASCT risk factors for relapse: primary refrac-
tory HL (i.e., CR not achieved with frontline chemother-
apy), relapsed HL with a duration of initial remission < 12
months, or extranodal involvement at the start of pre-
ASCT HDC. After a median of 30months’ follow-up, PFS
per independent review was significantly longer with bren-
tuximab vedotin compared with placebo (median PFS of
42.9 vs 24.1months [HR 0.57; 95% CI 0.40–0.81]; p =
0.0013) [65]. PFS benefit was consistent across pre-specified
subgroups, including patients with primary refractory HL
and those who relapsed < 12months after frontline therapy.
After 5 years of follow-up, brentuximab vedotin continued
to demonstrate sustained PFS benefit (HR 0.52; 95% CI
0.38–0.72), with 5-year per investigator PFS rates of 59%
versus 41% with placebo, implying that a considerable pro-
portion of these patients might have been cured [17]. This
long-term PFS benefit with brentuximab vedotin was more
pronounced in patients with higher numbers of pre-ASCT
risk factors, which included relapse within < 12months or
refractoriness to frontline therapy, best response of PR or
stable disease (SD) to most recent salvage therapy, extrano-
dal disease at pre-ASCT relapse, B-symptoms at pre-
transplant relapse, or ≥ 2 prior salvage therapies. An OS
analysis has not yet been performed, as the planned num-
ber of events has not been reached. Brentuximab vedotin
consolidation was well tolerated in the AETHERA study,
with 93 of 167 patients (56%) experiencing grade 3/4 AEs
[65]. Sixty-seven percent of brentuximab vedotin-treated
patients experienced some level of peripheral neuropathy,
90% of which had either completely resolved or decreased
in severity after 5 years’ follow-up [17].
The results of the AETHERA study are reflected in the
HL treatment guidelines developed by ESMO and NCCN,
and the lymphoma post-ASCT maintenance therapy guide-
lines developed by a joint expert panel consisting members
of American Society for Blood and Marrow Transplant-
ation (ASBMT), Center for International Blood and Mar-
row Transplant Research (CIBMTR), and EBMT [10, 11,
36]. ESMO guidelines recommend consolidation with bren-
tuximab vedotin following HDC-ASCT in patients present-
ing with ≥ 1 of the following risk factors: primary disease
progression, early disease recurrence after the end of front-
line treatment (< 12months), and extranodal disease at the
time of relapse, without specifying the duration of consoli-
dation therapy [11]. NCCN recommend brentuximab vedo-
tin for 1 year for patients with a high risk of relapse, defined
as ≥ 2 of the following risk factors: remission lasting < 1
year, extranodal involvement, PET-positive response at
time of transplant, B symptoms, and/or > 1 salvage/subse-
quent therapy regimen [10]. The ASBMT, CIBMTR, and
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Table 3 Novel targeted post-ASCT consolidative options in development or approved for use in R/R HL




phase III AETHERA study
(NCT01100502) [17, 65]
Consolidation therapy after ASCT in
patients with HL at high risk of
progression or relapse (n = 165
brentuximab vedotin arm)
• 2-year PFS rate: 63%
• 5-year PFS rate: 59%
• Grade 3/4 AEs: 16%
• Peripheral neuropathy: 67%
(90% of which had improved or
completely resolved after 5
years’ follow-up)
Camidanlumab tesirine (anti-
CD25; monotherapy) phase I
study (NCT00516217) [66]
R/R HL (median 5 prior lines; n = 26) • ORR 81%
• CR 50%




phase III (NCT01034163) [67]
Consolidation therapy after HDC and
ASCT in patients with HL at high risk of
relapse (n = 27 panobinostat arm)
Study discontinued early due to
poor accrual (41/367 planned
patients enrolled), so efficacy not
formally evaluated











R/R cHL after ASCT and brentuximab
vedotin




Post-ASCT consolidation therapy in
patients with R/R cHL who had
achieved a CR or PR with salvage
chemotherapy (N = 31)
• PFS rate at 18 months: 82%
• OS rate at 18 months: 100%
• Grade≥ 2 AEs: 80%
• Grade≥ 3 AEs: 30%
• Immune-related AEs: 43%
Galiximab (anti-CD80) phase II
CALGB 50602 study
(NCT00516217) [71]
R/R HL; median 3 prior regimens (n =
29)
• ORR 10.3%
• Median PFS 1.6 months




R/R HL (n = 37) • ORR 13.5% • Grade 3/4 AEs: 65% (HL and
NHL)
TNX-650 (anti-IL-13) phase I/II
study (NCT00441818)
Refractory HL • Study in progress
Relatlimib (anti-LAG-3) phase I/
II study with/without
nivolumab (NCT02061761)
R/R HL • Study in progress
AMG655 (anti-TRAIL) with
bortezomib or vorinostat
phase Ib study (NCT00791011)
R/R Lymphoma • No longer in development
RFT5-SPMT-dgA (anti-CD25) R/R HL • No longer in development
Alemtuzumab (anti-CD52)
phase II study with dose-
adjusted-EPOCH regimen
(NCT01030900)




monotherapy) phase I study
complete; phase II ongoing
(NCT02321592) [73]









• 6-month PFS 77%





RELY-30 phase I study
(NCT02917083) [75]
R/R HL
Median 5 prior therapies (n = 14)
• CR 58% • Not reported
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EBMT panels recommend post-ASCT consolidation with
brentuximab vedotin for a maximum of 16 cycles every 3
weeks, or until unacceptable toxicity or disease relapse
(whichever occurs first) for brentuximab vedotin-naïve pa-
tients with cHL and one or more high-risk features as de-
fined by the AETHERA study [36]. The panel do not
recommend brentuximab vedotin post-ASCT consolida-
tion in patients whose HL has shown signs of refractori-
ness to prior treatment with brentuximab vedotin;
however, high-risk patients with relapsed disease and lim-
ited prior exposure to brentuximab vedotin (~ 4–6 cycles)
prior to ASCT and no evidence of brentuximab-vedotin-
refractory disease, were recommended for brentuximab
vedotin consolidation.
Novel consolidation options
Following demonstration of the efficacy of brentuximab
vedotin as consolidation in post-ASCT HL treatment, clin-
ical studies to assess the efficacy of other anti-tumor agents,
such as chemotherapies and checkpoint inhibitors, have
been initiated. Novel therapies including ADCs, bispecific
antibodies, and chimeric antigen receptor-modified T
(CAR-T) cells are under investigation in R/R HL and other
lymphomas, and may be an option for post-ASCT consoli-
dation in the future. These are discussed briefly below.
ADCs One other ADC is in development for the treat-
ment of R/R HL. Camidanlumab tesirine is a human
anti-CD25 monoclonal antibody conjugated to a potent
pyrrolobenzodiazepine dimer toxin. A phase I, first-in-
human study reported an ORR of 81% in 26 patients
with R/R cHL in the 45 μg/kg dose group, with 50% CR.
Grade ≥ 3 treatment-emergent adverse events were re-
ported in 62% of patients (Table 3) [66].
Histone deacetylase inhibitors Panobinostat has been
investigated as consolidation therapy for patients with
HL in a phase III study that was discontinued due to
poor accrual [67].
Nivolumab Preclinical analyses of lymphoma cells re-
vealed the presence gene amplification of programmed
cell death-1 (PD-1) ligand [79], raising the prospect of
anti-PD-1 agents as therapeutic agents in HL. Nivolumab,
a fully human anti-PD-1 monoclonal antibody, was ap-
proved for use as monotherapy in adults with R/R cHL
after ASCT and brentuximab vedotin based on the results
of the phase II CheckMate 205 study [68, 69]. After a me-
dian follow-up of 18months, ORR per independent review
was 69%, ranging from 65 to 73% across brentuximab
vedotin-naïve and pre- and post-ASCT brentuximab
vedotin-treated cohorts (Table 3). The safety and efficacy
of nivolumab consolidation is being assessed in patients
with HL, who are at risk of relapse or progression after re-
ceipt of an ASCT, in a single-arm phase II study
(NCT03436862).
Pembrolizumab Pembrolizumab is a humanized anti-
PD-1 monoclonal antibody that is also being investigated
in the relapsed HL post-ASCT consolidation setting [80].
In the phase II KEYNOTE-087 study of pembrolizumab
in patients with R/R cHL, ORR per independent review
was 72% (95% CI 65–78) after a median follow-up of 27.6
months [81]. The activity of pembrolizumab is also being
assessed by Armand et al. in an ongoing multi-cohort
phase II study in patients with R/R cHL who had achieved
a CR or PR with first salvage chemotherapy (see Table 3)
[70]; in contrast in the AETHERA study, patients were re-
quired to have achieved a CR, PR, or SD with salvage
chemotherapy [65]. The primary endpoint, PFS at 18
months, was met, with a PFS rate of 82% for the evaluable
patients; OS rate at 18months was 100%.
Other monoclonal antibodies In addition to PD-1,
other targets under investigation include CD80, CD40,
IL-13, LAG-3, TRAIL, CD25, and CD52. Early data for
the anti-CD80 monoclonal antibody galiximab, and luca-
tumumab, which targets CD40, are not very promising,
with ORRs around 10–14% (Table 3) [71, 72]. Anti-
bodies against CD25 and TRAIL are no longer under de-
velopment [82].
Bispecific antibodies The bispecific antibody AFM13
targets CD30 and CD16a to recruit natural killer cells to
CD30-positive malignancies. A monotherapy study in 26
heavily-treated R/R HL patients demonstrated mild
Table 3 Novel targeted post-ASCT consolidative options in development or approved for use in R/R HL (Continued)
Targeted agent Treatment setting Efficacy Safety
Phase Ib/II study [76] R/R HL
Median 7.5 prior therapies (n = 22)




Heavily pretreated patients (n = 18)
• ORR 39%
• Median PFS 6 months
• Grade≥ 3 AEs in 2 patients
Anti-LMP1/2 phase I study
(NCT00671164) [78]




EPOCH etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; NHL non Hodgkin lymphoma
Sureda et al. BMC Cancer         (2020) 20:1088 Page 8 of 14
efficacy (ORR 11.5%, rising to 23% in the higher dose
group; n = 13) with a good safety profile [73]. A phase Ib
study (KEYNOTE-206) combining AFM13 with pembroli-
zumab resulted in a much improved ORR of 88% (Table
3), which also compares favorably with rates seen with
pembrolizumab alone [74].
CAR-T cells CAR-T cell therapies targeting CD30,
CD123, and Epstein-Barr virus (EBV)-related proteins
are in development for the treatment of cHL, and are
showing promising early results. Two US-based groups
and one group in China have investigated CD30 CAR-T
cell therapy in heavily-pretreated R/R HL with ORR
rates of 67, 63, and 39%, respectively (Table 3) [75–77].
A pivotal phase II study (NCT04268706) is being
planned based on these encouraging results, and the US
Food and Drug Administration granted Regenerative
Medicine Advanced Therapy designation to this treat-
ment on March 2, 2020. CAR-T cell therapy targeting
the EBV antigens latent membrane protein 1 (LMP1)
and LMP2 has also shown an encouraging ORR of 62%,
with 52% CR, in patients with R/R lymphoma [78].
Post-ASCT radiotherapy HL is extremely sensitive to
radiotherapy, even after multiple lines of chemotherapy;
however, there is a lack of large prospective randomized
studies to evaluate the role of post-ASCT consolidation
radiotherapy. It is generally believed that radiation-naïve
patients with localized residual lymphoma post-salvage
therapy or post-ASCT, could benefit from radiotherapy
before signs of progressive systemic lymphoma develop.
Retrospective analyses of patients treated with radiother-
apy as a post-ASCT salvage or consolidation option in
the clinic have shown variable effectiveness.
In the post-ASCT consolidation setting, radiotherapy has
shown some promise with significant improvements in
local control at 36months post-ASCT in patients receiving
radiotherapy compared with no radiotherapy (78% vs 48%,
p = 0.02) accompanied by limited toxicity [83]. Wilke et al.
found more promising results in radiotherapy vs no radio-
therapy regimens, with significant improvements in 2-year
PFS (67% vs 42%, p < 0.01), which could also be seen in pa-
tients with bulky disease (62% vs 39%, p = 0.02), B-
symptoms (48% vs 28%, p = 0.05), primary-refractory dis-
ease (47% vs 32%, p = 0.02), and those with a PR per pre-
transplant imaging (47% vs 32%, p = 0.02) [84]. However,
neither of these analyses were able to demonstrate a signifi-
cant improvement in OS with consolidative radiotherapy.
A single-institution analysis of 56 patients by Goda
et al. found that in patients who had failed ASCT and
received radiotherapy as a salvage option (salvage radi-
ation therapy [sRT] alone in 34 patients and sRT plus
chemotherapy in 22 patients), ORR was 84% (CR = 36%;
PR = 48%) with a median OS of 40.8 months and 5-year
OS of 29% [85]. The 2-year systemic PFS of 16% and
overall disease control rate of 17% were disappointing,
whereas local PFS at 2 years was 65%, leading the au-
thors to conclude that radiotherapy may be of use for
palliation of incurable HL.
The paucity of consistent data supporting the use of
post-ASCT radiotherapy are reflected in the heteroge-
neous adoption of this approach in European clinical
practice, other than to treat localized disease.
The challenge of demonstrating OS benefit in post-ASCT R/
R HL
Demonstration of an OS benefit remains the ideal clin-
ical endpoint in the oncological studies, representing the
time from randomization until death. Salvage with
HDC-ASCT is an effective approach that can be further
improved by consolidation strategies in high-risk pa-
tients [65]; however, owing to the effectiveness of tar-
geted therapies applied later in the disease course, it can
take many years to accumulate enough survival events to
demonstrate a statistically significant difference in OS
between an experimental therapy and the placebo/con-
trol arm. In the AETHERA study, patients had lengthy
post-ASCT PFS and OS, with some patients not relaps-
ing during follow-up, i.e., potentially achieving a cure
[65]. After a median follow-up of 5 years there were still
insufficient OS events to draw any conclusions on the
efficacy of brentuximab vedotin compared with placebo
in terms of impact on OS [17], and this may be further
complicated by the use of subsequent checkpoint inhibi-
tors. Crucially, AETHERA permitted patients in the pla-
cebo arm to crossover to the brentuximab arm, resulting
in 87% of patients in the placebo arm eventually receiv-
ing brentuximab vedotin monotherapy as a subsequent
therapy, further confounding assessment of the impact
of brentuximab vedotin on OS [17, 65].
Based on the challenges faced when using OS as an end-
point, the European Medicines Agency recommended that
time to second subsequent therapy (TTSST) is used as a
measure of ongoing disease control and an alternative to
OS (Fig. 1). TTSST is defined as the time between treat-
ment initiation and the start of the third line of treatment
(second subsequent therapy) and can be used to assess
continuous lymphoma control in patient populations at
high risk of relapse, in which multiple additional therapies
are often used [86, 87].
In a post hoc analysis of the AETHERA study at 5
years, significantly fewer patients in the brentuximab
vedotin arm had a TTSST event compared with the pla-
cebo arm (36% vs 46%, p < 0.0001), implying that 64% of
brentuximab vedotin-treated patients had not received
≥ 2 subsequent therapies for HL or died, versus 54% in
the placebo arm. Furthermore, subsequent transplants,
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including allo-SCT, were more common in the placebo
arm than the brentuximab vedotin arm [17, 65].
Discussion
The advent of treatment strategies and the consideration
of CMR before ASCT has improved patient outcomes in
the R/R HL setting; however, a considerable number of
patients continue to progress or relapse and display dis-
mal post-transplant outcomes. Appropriate utilization of
post-ASCT consolidation now appears to be a promising
and widely-applicable strategy.
The introduction of brentuximab vedotin as a post-ASCT
consolidation option has significantly improved patient out-
comes in terms of PFS (30% reduction in PFS events com-
pared with placebo) and reduced the need for second
subsequent therapy (36% of brentuximab vedotin patients
compared with 46% of placebo patients) [17]. The persist-
ence of these outcomes after 5 years’ follow-up demonstrate
the benefits provided by brentuximab vedotin consolidation.
Currently, there is a paucity of published data and guid-
ance on the utility of biomarkers in the R/R HL consolida-
tion setting. The AETHERA study found that the benefit
of brentuximab vedotin was more pronounced in patients
with additional pre-ASCT risk factors for relapse. At 5
years, the HR for PFS was 0.42 (95% CI 0.30–0.60) in pa-
tients with ≥ 2 risk factors and 0.39 (95% CI 0.26–0.60) in
those with ≥ 3 risk factors [17]. Therefore, prognostic fac-
tors should be considered when making treatment deci-
sions in the R/R HL setting.
PET-positivity is a known negative prognostic factor;
however, large-scale adequately-powered studies are re-
quired to obtain meaningful data to appropriately quantify
the effect of the persistence and the magnitude of pre-
ASCT PET-positivity on the outcome of ASCT. In the
AETHERA study, PET scans before ASCT were not man-
dated in the study protocol, reflecting clinical practice at
the time [65]. Although PET scans were performed in
approximately two-thirds of patients, objective criteria
were not required for interpretation. The benefit of bren-
tuximab vedotin appeared to be reduced in patients who
were PET-negative before ASCT, according to a univariate
analysis. The role of biomarkers in this setting is evolving.
PET scans are now a requirement for all studies and meta-
bolic tumor volume is also emerging as a promising new
prognostic biomarker.
MRD has been used as surrogate parameter for treatment
effectiveness in follicular lymphoma and MCL [61, 62, 88–
91] and further studies are needed to demonstrate the clin-
ical utility of MRD as a biomarker for personalization of
HL consolidation strategies. Despite the paucity of evidence
supporting routine use of MRD assessment as part of con-
solidation, the marked PFS benefit seen at 4months in the
AETHERA study, with continued benefit seen over the 5-
year follow-up period [17, 65] supports the rationale for
extended use of consolidation therapy; in the case of the
AETHERA study for up to 1 year after ASCT, to minimize
the risk of relapse.
There are few publications characterizing the utility of
similar markers in patients with HL [92–94]. Using a highly
sensitive next-generation sequencing method, Oki et al.
demonstrated the feasibility of identifying lymphoma-
specific immunoglobulin gene segments in the peripheral
blood of patients with cHL [92]. The authors postulated
that this new blood-based method could be used to moni-
tor disease burden and provide prognostic information for
patients with cHL. In an exploratory analysis of patients en-
rolled in AETHERA, Bachanova et al. found that serum
levels of thymus and activation-regulated chemokine may
also be useful in identifying HL patients at increased risk of
disease progression following ASCT treatment [94]. More-
over, Camus et al. determined that recurrent exportin 1
gene mutations in tumor and cell-free circulating DNA can
be used as a novel biomarker in patients with cHL using a
highly sensitive digital PCR technique [93]. Non-invasive
Fig. 1 Time to second subsequent therapy as an endpoint. Progression-free survival is defined as the length of time between treatment initiation
and progressive disease or death, whichever occurs first. Overall survival is defined as the length of time during and after the treatment of a
disease until death from any cause. In contrast, time to second subsequent therapy is defined as the length of time between treatment initiation
and the start of the third line of treatment (second subsequent therapy)
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methods utilizing cell-free circulating DNA to identify som-
atic mutations represent a promising advance in the man-
agement of HL. Molecular monitoring using cell-free DNA
is emerging as a highly sensitive screening tool that has po-
tential for future screening in hematologic malignancies
[95, 96]. More studies are needed to further elucidate these
methods fully in patients with HL.
The impact of post-ASCT consolidation therapy on qual-
ity of life (QoL) needs to be carefully considered, as patients
may have already experienced poor health-related QoL dur-
ing HDC and ASCT [97, 98]. Peripheral neuropathy is a
common AE with anti-microtubule-directed agents, and
was the most frequently occurring AE with brentuximab
vedotin in the AETHERA study [65]. Although 67% of pa-
tients in this study experienced peripheral neuropathy, of
which the majority were sensory events, only 13% of pa-
tients experienced grade 3 events, and there were no grade
4 events. In a QoL analysis of the AETHERA study, there
were no significant differences in mean European Quality
of Life five dimensions scores between patients with and
without peripheral neuropathy within the brentuximab
vedotin arm at any time point [99].
Consensus recommendations from ASBMT, CIBMTR,
and EBMT provide strong support for the use of brentuxi-
mab vedotin as consolidation/maintenance after ASCT in
brentuximab vedotin-naïve patients with cHL based on
data from the AETHERA study (grade A recommenda-
tion; there is good research-based evidence to support the
recommendation) [36]. Authors did not provide any spe-
cific guidance on use of brentuximab vedotin salvage ther-
apy and the expert panel also assigned a grade C
recommendation (the recommendation is based on expert
opinion and panel consensus) to the use of brentuximab
vedotin as post-ASCT consolidation/maintenance in pa-
tients with limited prior exposure to brentuximab vedotin
(4–6 cycles) [36]. With the approval of brentuximab vedo-
tin (plus doxorubicin, vinblastine, and dacarbazine) in pre-
viously untreated patients with advanced cHL there will
likely be future changes to the currently recommended
post-transplant strategies.
Conclusions
In summary, post-ASCT consolidation (including radio-
therapy) improves outcomes in patients with R/R HL who
require ASCT, with early intervention providing the great-
est benefits. More potent frontline and pre-ASCT salvage
regimens also show promise in improving outcomes in this
patient group, however, they have not yet been formally
tested in phase III studies. Checkpoint inhibitors may be
used for patients who have already received brentuximab
vedotin. Approval of novel targeted agents is expected to
further improve outcomes and provide additional treatment
options in the coming age of personalized medicine.
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